Alvotech and Bioventure Receives Approval of AVT02 (biosimilar, adalimumab) from Egyptian Drug Authority in Egypt
Shots:
- Alvotech and Bioventure have received approval from the Egyptian Drug Authority to manufacture and distribute AVT02, a biosimilar for Humira for the treatment of RA and multiple other inflammatory diseases, under the trade name Adalimumab-EVA
- Alvotech will lead the development and production of the product while Bioventure is responsible for commercialization. Alvotech’s focuses on increasing patient access globally to more affordable biologics
- Bioventure serves as the strategic partner of Alvotech for marketing AVT02 and other biosimilar candidates in the MENA regions. AVT02 is currently marketed in multiple EU countries and Canada
Ref: Alvotech | Image: Alvotech
Related News:- Alvotech Receives Complete Response Letter on Second BLA for AVT02
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
